MCM
LAB icon

MAI Capital Management’s Standard BioTools LAB Stock Holding History

MAI Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$661 Buy
718
+418
+139% +$506 ﹤0.01% 4319
2025
Q4 		$384 Hold
300
– – ﹤0.01% 3905
2025
Q3 		$390 Hold
300
– – ﹤0.01% 3650
2025
Q2 		$360 Hold
300
– – ﹤0.01% 3810
2025
Q1 		$324 Sell
300
-343
-53% -$482 ﹤0.01% 3272
2024
Q4 		$1.13K Buy
+643
New +$1.2K ﹤0.01% 3166

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

MAI Capital Management's LAB Position: Q1 2026 in Review

MAI Capital Management increased its Standard BioTools (LAB) stake by 139% in Q1 2026, buying an estimated $506 and bringing the position to 718 shares worth $661. The position accounts for ﹤0.01% of the portfolio, ranked #4319.

MAI Capital Management first reported a position in LAB in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.13K in Q4 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • MAI Capital Management held 718 shares of Standard BioTools worth $661 as of Q1 2026.
  • MAI Capital Management bought 418 Standard BioTools shares in Q1 2026, an estimated $506.
  • Standard BioTools made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4319 holding.
  • MAI Capital Management first reported a position in Standard BioTools in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Standard BioTools position peaked at $1.13K in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.